ArticleESC heart failure2019
Cardiovascular biomarkers predict post-discharge re-hospitalization risk and mortality among Swedish heart failure patients.
Article in ESC heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Prognostic Value of Plasma Big Endothelin-1 in Patients Hospitalized for Heart Failure.Korean circulation journal · 2025Article
- Prediction of 90 day readmission in heart failure with preserved ejection fraction by interpretable machine learning.ESC heart failure · 2024Article
- Prognostic effect of systematic geriatric assessment on patients with acute heart failure.ESC heart failure · 2024Article
- Value of the triglyceride-glucose index and related parameters in heart failure patients.Frontiers in cardiovascular medicine · 2024Review
- Risk factors of readmission and the impact of outpatient management in heart failure patients: A national study in Japan.ESC heart failure · 2023Article
- Natriuretic peptide level at heart failure diagnosis and risk of hospitalisation and death in England 2004-2018.Heart (British Cardiac Society) · 2022Article
- Differences According to Age in the Diagnostic Performance of Cardiac Biomarkers to Predict Frailty in Patients with Acute Heart Failure.Biomolecules · 2022Article
- Association of C-Terminal Pro-Endothelin-1 with Mortality in the Population-Based KORA F4 Study.Vascular health and risk management · 2022Article
- Arterial Stiffness, Subendocardial Impairment, and 30-Day Readmission in Heart Failure Older Patients.Frontiers in cardiovascular medicine · 2022Article
- Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases.Frontiers in cardiovascular medicine · 2022Review
- A year in heart failure: an update of recent findings.ESC heart failure · 2021Review
- Time-to-event prediction analysis of patients with chronic heart failure comorbid with atrial fibrillation: a LightGBM model.BMC cardiovascular disorders · 2021Article
- Mid-Regional Proadrenomedullin as a New Biomarker of Kidney and Cardiovascular Diseases-Is It the Future?Journal of clinical medicine · 2021Review
- Weight loss, malnutrition, and cachexia in COVID-19: facts and numbers.Journal of cachexia, sarcopenia and muscle · 2021Article
- Prevalence and Prognostic Value of Heart Failure Stages: An Elderly Inpatient Based Cohort Study.Frontiers in medicine · 2021Article
- Prevalence and Prognostic Significance of Frailty in Gerontal Inpatients With Pre-clinical Heart Failure: A Subgroup Analysis of a Prospective Observational Cohort Study in China.Frontiers in cardiovascular medicine · 2020Article
- Cardiovascular biomarkers predict post-discharge re-hospitalization risk and mortality among Swedish heart failure patients.ESC heart failure · 2019Article
- Biomarkers in Heart Failure.Arquivos brasileiros de cardiologia · 2019Article
- Pro-adrenomedullin as a prognostic biomarker in patients with heart failure: A systematic review and meta-analysis.JRSM cardiovascular diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimThe aim of this study was to assess the predictive role of biomarkers, associated with cardiovascular stress and its neuroendocrine response as well as renal function, in relation to mortality and risk of re-hospitalization among consecutive patients admitted because of heart failure (HF). METHODS AND
resultsA total of 286 patients (mean age, 75 years; 29% women) hospitalized for newly diagnosed or exacerbated HF were analysed. Associations between circulating levels of mid-regional pro-adrenomedullin (MR-proADM), copeptin, C-terminal pro-endothelin-1, N-terminal pro-brain natriuretic peptide (NT-proBNP), cystatin C, and all-cause mortality as well as risk of re-hospitalization due to cardiac causes were assessed using multivariable Cox regression models. A two-sided Bonferroni-corrected P-value of 0.05/5 = 0.010 was considered statistically significant. All biomarkers were related to echocardiographic measurements of cardiac dimensions and function. A total of 57 patients died (median follow-up time, 17 months). In the multivariable-adjusted Cox regression analyses, all biomarkers, except C-terminal pro-endothelin-1, were significantly associated with increased mortality: NT-proBNP [hazard ratio (HR) 1.85, 95% confidence interval (CI) 1.17-2.17; P = 4.0 × 10
conclusionsAmong patients hospitalized for HF, elevated plasma levels of NT-proBNP, MR-proADM, copeptin, and cystatin C are associated with higher mortality after discharge, whereas NT-proBNP is the only biomarker that predicts the risk of re-hospitalization due to cardiac causes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.